94 related articles for article (PubMed ID: 1903197)
1. gsp mutations in human thyroid tumours.
Suarez HG; du Villard JA; Caillou B; Schlumberger M; Parmentier C; Monier R
Oncogene; 1991 Apr; 6(4):677-9. PubMed ID: 1903197
[TBL] [Abstract][Full Text] [Related]
2. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
3. A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours.
Clementi E; Malgaretti N; Meldolesi J; Taramelli R
Oncogene; 1990 Jul; 5(7):1059-61. PubMed ID: 2115641
[TBL] [Abstract][Full Text] [Related]
4. Absence of G(s)alpha gene mutations in childhood thyroid tumors after Chernobyl in contrast to sporadic adult thyroid neoplasia.
Waldmann V; Rabes HM
Cancer Res; 1997 Jun; 57(12):2358-61. PubMed ID: 9192808
[TBL] [Abstract][Full Text] [Related]
5. Expression of mutationally activated G alpha s stimulates growth and differentiation of thyroid FRTL5 cells.
Muca C; Vallar L
Oncogene; 1994 Dec; 9(12):3647-53. PubMed ID: 7526317
[TBL] [Abstract][Full Text] [Related]
6. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms.
Matsuo K; Friedman E; Gejman PV; Fagin JA
J Clin Endocrinol Metab; 1993 Jun; 76(6):1446-51. PubMed ID: 8501149
[TBL] [Abstract][Full Text] [Related]
7. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
[TBL] [Abstract][Full Text] [Related]
8. GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours.
Vallar L
Biochem Soc Symp; 1990; 56():165-70. PubMed ID: 2124121
[TBL] [Abstract][Full Text] [Related]
9. G protein and thyrotropin receptor mutations in thyroid neoplasia.
Esapa C; Foster S; Johnson S; Jameson JL; Kendall-Taylor P; Harris PE
J Clin Endocrinol Metab; 1997 Feb; 82(2):493-6. PubMed ID: 9024242
[TBL] [Abstract][Full Text] [Related]
10. Absence of activating mutations of the genes encoding the alpha-subunits of G11 and Gq in thyroid neoplasia.
Ringel MD; Saji M; Schwindinger WF; Segev D; Zeiger MA; Levine MA
J Clin Endocrinol Metab; 1998 Feb; 83(2):554-9. PubMed ID: 9467574
[TBL] [Abstract][Full Text] [Related]
11. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor: a role for thyroid tumourigenesis?
Russo D; Arturi F; Chiefari E; Filetti S
Forum (Genova); 1999; 9(2):166-75. PubMed ID: 10385711
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of the stimulatory G protein alpha-subunit mutations in autonomously functioning thyroid adenomas in Japan.
Tanaka K; Nagayama Y; Takeshita A; Namba H; Yamashita S; Niwa M; Nagataki S
Thyroid; 1996 Jun; 6(3):195-9. PubMed ID: 8837326
[TBL] [Abstract][Full Text] [Related]
15. Absence of activating mutations in ras and gsp oncogenes in a cohort of nine patients with sporadic pediatric thyroid tumors.
Pauws E; Tummers RF; Ris-Stalpers C; de Vijlder JJ; Voûte T
Med Pediatr Oncol; 2001 Jun; 36(6):630-4. PubMed ID: 11344494
[TBL] [Abstract][Full Text] [Related]
16. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas.
Derwahl M; Hamacher C; Russo D; Broecker M; Manole D; Schatz H; Kopp P; Filetti S
J Clin Endocrinol Metab; 1996 May; 81(5):1898-904. PubMed ID: 8626855
[TBL] [Abstract][Full Text] [Related]
18. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
20. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
Bouras M; Parvaz P; Berger N; Paulin C; Revol A
Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
